These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34917077)

  • 1. Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines.
    Wang Y; Tan H; Yu T; Chen X; Jing F; Shi H
    Front Immunol; 2021; 12():755401. PubMed ID: 34917077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
    You W; Ouyang J; Cai Z; Chen Y; Wu X
    Front Immunol; 2022; 13():827506. PubMed ID: 35874675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines.
    Chen Y; Zhang C; Li Y; Tan X; Li W; Tan S; Liu G
    Sci Rep; 2024 Feb; 14(1):3219. PubMed ID: 38331967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immune subtypes of lung adenocarcinoma identified through bioinformatic analysis.
    Qin FL; Xu ZY; Yuan LQ; Chen WJ; Wei JB; Sun Y; Li SK
    FEBS Open Bio; 2020 Sep; 10(9):1921-1933. PubMed ID: 32686362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying novel tumor-related antigens and immune phenotypes for developing mRNA vaccines in lung adenocarcinoma.
    Zhou B; Zang R; Zhang M; Song P; Liu L; Bie F; Peng Y; Bai G; Gao S
    Int Immunopharmacol; 2022 Aug; 109():108816. PubMed ID: 35504200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
    Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes.
    Zhou F; Wang M; Wang Z; Li W; Lu X
    BMC Cancer; 2024 Jan; 24(1):28. PubMed ID: 38166691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
    Liao Y; He D; Wen F
    Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
    Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
    Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
    Wang Z; Chen X
    Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.